These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 38531949)

  • 1. Are there new relevant therapeutic endpoints in the modern era of the BCR::ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia?
    Kantarjian H; Branford S; Breccia M; Cortes J; Haddad FG; Hochhaus A; Hughes T; Issa GC; Jabbour E; Nicolini FE; Sasaki K; Xavier-Mahon F
    Leukemia; 2024 May; 38(5):947-950. PubMed ID: 38531949
    [No Abstract]   [Full Text] [Related]  

  • 2. Suboptimal molecular response to tyrosine kinase inhibition associated with acquisition of a T240A ABL1 kinase domain mutation in a patient with chronic myeloid leukemia.
    Langabeer SE; Haslam K; Crampe M; MacDonagh B; McHugh J
    Exp Oncol; 2019 Mar; 41(1):82-83. PubMed ID: 30932408
    [No Abstract]   [Full Text] [Related]  

  • 3. K356dup--an in-frame insertion in the BCR-ABL gene in an imatinib-resistant chronic myeloid leukemia.
    Gniot M; Wasilewska EM; Lewandowski K
    Int J Lab Hematol; 2012 Dec; 34(6):e3-6. PubMed ID: 25998099
    [No Abstract]   [Full Text] [Related]  

  • 4. Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1
    Mian AA; Haberbosch I; Khamaisie H; Agbarya A; Pietsch L; Eshel E; Najib D; Chiriches C; Ottmann OG; Hantschel O; Biondi RM; Ruthardt M; Mahajna J
    Ann Hematol; 2021 Aug; 100(8):2023-2029. PubMed ID: 34110462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation.
    Pemovska T; Johnson E; Kontro M; Repasky GA; Chen J; Wells P; Cronin CN; McTigue M; Kallioniemi O; Porkka K; Murray BW; Wennerberg K
    Nature; 2015 Mar; 519(7541):102-5. PubMed ID: 25686603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives.
    Massimino M; Stella S; Tirrò E; Pennisi MS; Vitale SR; Puma A; Romano C; DI Gregorio S; Tomarchio C; DI Raimondo F; Manzella L
    Anticancer Res; 2020 May; 40(5):2457-2465. PubMed ID: 32366389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New concepts for CML clonality.
    Khorashad JS; Deininger MW; O'Hare T
    Oncotarget; 2013 Jan; 4(1):7-8. PubMed ID: 23448894
    [No Abstract]   [Full Text] [Related]  

  • 8. Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor-Sensitive and -Resistant Chronic Myeloid Leukemia.
    Ben-Batalla I; Erdmann R; Jørgensen H; Mitchell R; Ernst T; von Amsberg G; Schafhausen P; Velthaus JL; Rankin S; Clark RE; Koschmieder S; Schultze A; Mitra S; Vandenberghe P; Brümmendorf TH; Carmeliet P; Hochhaus A; Pantel K; Bokemeyer C; Helgason GV; Holyoake TL; Loges S
    Clin Cancer Res; 2017 May; 23(9):2289-2300. PubMed ID: 27856601
    [No Abstract]   [Full Text] [Related]  

  • 9. Presence of a new BCR-ABL kinase domain mutation, C330G in an imatinib naive patient with chronic myeloid leukemia: very low prevalence of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia from eastern India.
    Kuila N; Dash N; Sahoo DP; Pattnayak NC; Biswas G; Chakraborty S
    Leuk Lymphoma; 2009 Apr; 50(4):663-6. PubMed ID: 19373669
    [No Abstract]   [Full Text] [Related]  

  • 10. Thinking outside of ABL1 for resistance to tyrosine kinase inhibitors: a perspective of the SEPT9-ABL1 fusion protein.
    Hu T; Ciccarelli BT
    Leuk Res; 2014 Dec; 38(12):1399-400. PubMed ID: 25449686
    [No Abstract]   [Full Text] [Related]  

  • 11. Asciminib antagonizes transplantable BCR::ABL1-positive lymphoid blast crisis in vivo by targeting malignant stem cells.
    Chatain N; Baumeister J; Szymanski de Toledo MA; Wong DWL; Gupta S; Pannen K; Junge B; Brümmendorf TH; Boor P; Koschmieder S
    Leukemia; 2024 Aug; 38(8):1825-1830. PubMed ID: 38906962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Real-Time Quantitative PCR and Digital Droplet PCR for BCR-ABL1 Monitoring in Patients with Chronic Myeloid Leukemia.
    Franke GN; Maier J; Wildenberger K; Cross M; Giles FJ; Müller MC; Hochhaus A; Niederwieser D; Lange T
    J Mol Diagn; 2020 Jan; 22(1):81-89. PubMed ID: 31669230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 10 years of progress in chronic myelogenous leukemia.
    Jabbour E; Mathisen MS; O'Brien S
    J Natl Compr Canc Netw; 2012 Sep; 10(9):1049-53. PubMed ID: 22956803
    [No Abstract]   [Full Text] [Related]  

  • 14. Integrated drug profiling and CRISPR screening identify BCR::ABL1-independent vulnerabilities in chronic myeloid leukemia.
    Adnan Awad S; Dufva O; Klievink J; Karjalainen E; Ianevski A; Pietarinen P; Kim D; Potdar S; Wolf M; Lotfi K; Aittokallio T; Wennerberg K; Porkka K; Mustjoki S
    Cell Rep Med; 2024 May; 5(5):101521. PubMed ID: 38653245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma tyrosine kinase activity as a potential biomarker in BCR-ABL1-targeted therapy.
    Yeh CH; Abdool A; Bruey JM
    Cancer Biomark; 2010; 7(6):295-303. PubMed ID: 21694468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Finding the right BCR-ABL1 tyrosine kinase inhibitor: a case report of successful treatment of a patient with chronic myeloid leukemia and a V299L mutation using nilotinib.
    Elnair R; Galal A
    BMC Cancer; 2018 Nov; 18(1):1097. PubMed ID: 30419862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variant isoforms of BCR-ABL1 in chronic myelogenous leukemia reflect alternative splicing of ABL1 in normal tissue - letter.
    Khorashad JS; Milojkovic D; Reid AG
    Mol Cancer Ther; 2010 Jul; 9(7):2152. PubMed ID: 20571070
    [No Abstract]   [Full Text] [Related]  

  • 18. Early Prediction of Subsequent Molecular Response to Nilotinib in Patients with Chronic Myeloid Leukemia: Comparison of the Quantification of BCR-ABL1 Ratios Using ABL1 or GUSB Control Genes.
    Stuckey R; Casado LF; Colomer D; Gómez-Casares MT; Casas L; García-Gutierrez V; Sastre JL; Ramírez-Payer Á; Vall-Llovera F; Goñi MÁ; Xicoy B; Godoy AC; Núñez J; Mora I; Vallansot R; López-Lorenzo JL; Palomera L; Conesa V; Noya MS; Sánchez-Guijo F; Peña A; Bautista G; Steegmann JL
    J Mol Diagn; 2020 Oct; 22(10):1217-1224. PubMed ID: 32688056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel
    Malik S; Hassan S; Eşkazan AE
    Expert Rev Hematol; 2021 Nov; 14(11):975-978. PubMed ID: 34608829
    [No Abstract]   [Full Text] [Related]  

  • 20. ABL Kinase Domain Mutations in Iranian Chronic Myeloid Leukemia Patients with Resistance to Tyrosine Kinase Inhibitors.
    Shojaei M; Rezvani H; Azarkeivan A; Poopak B
    Lab Med; 2021 Mar; 52(2):158-167. PubMed ID: 32821940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.